The Oncology Institute, Inc. $TOI Shares Purchased by Maven Securities LTD

Maven Securities LTD raised its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 151.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 251,128 shares of the company’s stock after buying an additional 151,128 shares during the quarter. Maven Securities LTD’s holdings in Oncology Institute were worth $894,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new position in shares of Oncology Institute during the fourth quarter valued at approximately $31,000. Pekin Hardy Strauss Inc. bought a new position in Oncology Institute during the 4th quarter valued at $36,000. Cetera Investment Advisers boosted its stake in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares in the last quarter. State of Wyoming bought a new position in Oncology Institute during the 2nd quarter valued at $37,000. Finally, R Squared Ltd bought a new position in Oncology Institute during the 4th quarter valued at $41,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Price Performance

Oncology Institute stock opened at $5.18 on Tuesday. The company has a market capitalization of $511.99 million, a price-to-earnings ratio of -14.00 and a beta of 0.37. The Oncology Institute, Inc. has a one year low of $2.02 and a one year high of $5.57. The company’s fifty day moving average price is $4.03 and its two-hundred day moving average price is $3.47.

Oncology Institute (NASDAQ:TOI) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million. As a group, sell-side analysts anticipate that The Oncology Institute, Inc. will post -0.17 earnings per share for the current year.

Insider Activity

In related news, insider Yale Podnos sold 23,451 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $5.38, for a total value of $126,166.38. Following the completion of the sale, the insider owned 259,527 shares in the company, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohit Kaushal sold 38,433 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $3.50, for a total transaction of $134,515.50. Following the completion of the sale, the director owned 172,583 shares of the company’s stock, valued at approximately $604,040.50. The trade was a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have acquired 250,500 shares of company stock valued at $870,795 and have sold 119,170 shares valued at $461,183. 4.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TOI shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. B. Riley Financial increased their target price on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. BTIG Research increased their target price on Oncology Institute from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, June 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Oncology Institute in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Oncology Institute presently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.